FDA Grants Third Emergency-Use Authorization For H7N9 Flu Test
This article was originally published in The Gray Sheet
The April 25 emergency authorization covers the use of Arbor Vita Corp.’s rapid H7N9 assay in government laboratories on U.S. citizens who are suspected of exposure to the variant of avian flu in China.
You may also be interested in...
The agency’s diagnostic office is putting to the test new authority to grant emergency use authorization for a product before an emergency is officially declared, with an upcoming coronavirus test and a recently authorized flu test.
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
No device-related warning letters were released by the US FDA the week of 19 January.